Recent News

• 03.11.2025 - TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
• 03.10.2025 - TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
• 02.19.2025 - TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
• 12.12.2024 - TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
• 11.25.2024 - TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Recent Filings

• 02.14.2025 - 8-K Current report
• 02.07.2025 - S-4 Registration of securities, business combinations
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.03.2025 - 8-K Current report
• 12.23.2024 - S-8 Securities to be offered to employees in employee benefit plans
• 12.12.2024 - 8-K Current report
• 12.12.2024 - EX-99.1 EX-99.1